Excess reactive oxygen species (ROS) generation and inflammation may contribute to obesityassociated skeletal muscle insulin resistance. Ghrelin is a gastric hormone whose unacylated (UnAG) form is associated with whole-body insulin sensitivity in humans and may reduce oxidative stress in non-muscle cells in-vitro. We hypothesized that UnAG 1) lowers muscle ROS production and inflammation and enhances tissue insulin action in lean rats; 2) prevents muscle metabolic alterations and normalizes insulin resistance and hyperglycemia in high-fat diet (HFD)-induced obesity. In 12-week-old lean rats, UnAG (4-day, twice-daily subcutaneous 200µg-injections) reduced gastrocnemius mitochondrial ROS generation and inflammatory cytokines while enhancing AKT-dependent signaling and insulin-stimulated glucose uptake. In HFD-treated mice, chronic UnAG overexpression prevented obesity-associated hyperglycemia and whole-body insulin resistance (insulin-tolerance test), as well as muscle oxidative stress, inflammation and altered insulin signalling. In myotubes, UnAG consistently lowered mitochondrial ROS production and enhanced insulin signalling, while UnAG effects were prevented by siRNA-mediated silencing of the autophagy mediator ATG5. Thus, UnAG lowers mitochondrial ROS production and inflammation while enhancing insulin action in rodent skeletal muscle. In HFD-induced obesity, these effects prevent hyperglycemia and insulin resistance. Stimulated muscle autophagy could contribute to UnAG activities. These findings support UnAG as a therapeutic strategy for obesity-associated metabolic alterations.
Introduction
Clustered metabolic abnormalities including excess reactive oxygen species (ROS) generation and inflammation activation are proposed contributors to the onset of skeletal muscle insulin resistance (1) (2) (3) (4) (5) . Excess muscle ROS production and inflammation are indeed linked at the level of IκB/NF-κB activation and may cause insulin resistance by inhibiting insulin signalling downstream of insulin receptor (2, 3, 5) . Ghrelin is a peptide hormone predominantly secreted by the stomach whose acylated form (AG) is a major hypothalamic orexigenic signal (6, 7) .
Sustained AG administration causes weight gain and hyperglycemia despite enhanced muscle mitochondrial oxidative capacity (8, 9) by increasing food intake, hepatic gluconeogenesis and fat deposition in rodents (10, 11) . A comprehensive understanding of the metabolic impact of ghrelin has been however recently allowed by reports of independent more favourable effects of its unacylated form (UnAG). Although no specific UnAG receptor has been yet identified, UnAG counteracts glucogenic effects of AG as well as AG-induced hyperglycemia (10) , and negative associations have been reported between circulating UnAG and markers of whole-body insulin resistance in humans (12, 13) . Emerging antioxidant effects have been interestingly reported for UnAG in different cell types (14) (15) (16) (17) and we recently demonstrated that UnAG stimulates autophagy in rodent muscle, thereby also potentially lowering muscle oxidative stress through disposal of damaged mitochondria (18) . No information is however available 1) on the impact of UnAG on skeletal muscle ROS generation, inflammation and insulin action; 2) on whether UnAG prevents altered oxidative stress, inflammation and insulin action in obesity and diabetes.
We therefore studied lean rats and a transgenic mouse model of systemic UnAG overproduction (19) to test the hypothesis that UnAG 1) lowers mitochondrial ROS production and inflammation and enhances insulin action in lean rodent muscle; 2) normalizes high-fat diet (HFD)-induced muscle metabolic alterations, whole-body insulin resistance and hyperglycemia. In addition, effects of UnAG were verified in vitro in myotubes, where we also mechanistically tested the hypothesis that UnAG activites are at least partly mediated by positive modulation of autophagy.
Research Design and Methods

Experimental design
Exogenous UnAG administration Experiments were approved by the Animal Studies Committee at Trieste University. Twenty 12-week-old male Wistar rats (Harlan-Italy, San Pietro-alNatisone, Udine, Italy) were housed for two weeks in individual cages with a 12-h light-dark cycle at the University Animal Facility, with ad-libitum water and standard chow (Harlan 2018, 14.2 kJ/g). Animals were then randomly assigned to 4-day, twice-daily 200µg-subcutaneous injections of UnAG (n=10, Bachem, Bubendorf, CH) or vehicle (Ct, n=10, NaCl 0,9% w/v).
UnAG dose was based on previous studies in which equimolar AG modulated the same parameters (8) . Body weight and food intake were monitored daily; after the last injection, food was removed for three hours followed by anaesthesia (Tiobutabarbital 100 mg/kg, Tiletamine/Zolazepam (1:1) 40 mg/kg IP). Gastrocnemius and extensor digitorum longus (EDL) muscles were then surgically isolated and blood collected by heart puncture.
Transgenic UnAG overexpression Generation and characteristics of transgenic mice overexpressing UnAG (Tg Myh6/Ghrl) were previously described (19). Selective ghrelin overproduction in the heart, characterized by negligible acylating activity, results in 40-fold increment in circulating UnAG without AG modification. 14 Tg Myh6/Ghrl and 14 matched wild-type male mice underwent 16-week standard or HFD feeding (10% or 60% calories from fat; Research Diets, New Brunswick, NJ), and were sacrificed as described above. Insulin tolerance tests (ITT) were performed at 15 weeks of treatment by intraperitoneal insulin injection (Humulin-R, Lilly, Indianapolis, IN; 3 nmol/kg) after 4-h fasting. Blood glucose was measured from tail blood (AccuCheck Active, Roche, Basel, CH) immediately prior to injection and at 20, 40, 60, 80 min.
Myotube experiments C2C12 myoblasts were differentiated in myotubes (20). After 4-day incubation with differentiation medium and 18h-starvation, cells were treated with AG or UnAG (0.1, 0.5, 1µmol/l) for 48 h, collected and processed. In additional experiments, the potential role of autophagy in effects of UnAG was investigated by genomic silencing of the autophagy mediator ATG5 (18). SiRNA knockdown of ATG5 was performed by reverse transfection at final 25nM concentration with mouse ATG5 siRNA (M-064838-02-0005; Dharmacon) or with a non-targeting control siRNA #4 (D-001210-04-20; Dharmacon) using Lipofectamine RNAiMAX (Life Technologies). Twenty-four hours after transfection, culture medium was replaced and after thirty-six hours differentiated, treated and processed as above. ATG5 protein levels were quantified by western blot.
Analytical methods
Plasma insulin and non-esterified fatty acids (NEFA) Plasma insulin concentration was measured by ELISA (Ultrasensitive ELISA, DRG, Springfield, NJ). Plasma glucose and NEFA were determined by standard enzymatic-colorimetric assays (21,22). Ex vivo redox state Mitochondrial H 2 O 2 production was assessed in isolated intact mitochondria from tissues and cells using the Amplex Red (10µmol/l, Invitrogen, Carlsbad, CA)-HRP method, modified as previously reported and normalised by citrate synthase (CS) activity in the same mitochondrial preparation (22,23). Assay substrate concentrations (mmol/l) were: 8 glutamate, 4 malate (GM); 10 succinate (S); 4 glutamate, 2 malate, 10 succinate (GMS); 0.05 palmitoyl-Lcarnitine, 2 malate (PCM). Superoxide anion production sources in gastrocnemius muscle wholetissue homogenate were assessed using the lucigenin chemiluminescent method as described (22) and normalised by protein concentration (BCA assay, Pierce, Rockford IL, USA). The impact of subsequent addition of specific inhibitors on specific substrate-stimulated production rates was used to evaluate relative superoxide production from each source (Mitochondria: 5µmol/l CCCP on Succinate; NOS: 10mmol/l L-NAME on 10mmol/l L-Arginine; NADPH Oxidase: 200µmol/l DPI on 1mmol/l NADPH; Xanthine oxidase: 200µmol/l Oxypurinol on 500µmol/l Xanthine) as referenced.
Glutathione and antioxidant enzyme activities Total and oxidised glutathione were determined as referenced (24) on ~50mg of gastrocnemius cleaned and homogenised in ice-cold 5% (wt/vol.) metaphosphoric acid (20ml/g tissue). Reduced glutathione (GSH) was calculated as total minus oxidised fraction (GSSG). Commercial kits were used to measure catalase (Amplex Red Catalase Assay, Invitrogen, Carlsbad, CA) and glutathione peroxidase activities (Abcam, Cambridge, UK Electrophoretic mobility shift assay (EMSA) NF-κB binding activity was assessed by nonradioactive EMSA (22) with modifications. Equal amounts of nuclear protein were loaded for each sample. After incubation with polydeoxyinosinic-deoxycytidylic acid (0.05µg/µl) and double-stranded 3′-biotinylated DNA probe, electrophoretic separation of nuclear extracts was performed in 0.8% agarose gel. Band specificity evaluation and identification was performed by running a pooled sample pre-incubated for 20 min with excess unlabelled probe (1000x), antip65 (Millipore; 2µg) or anti-p105/p50 (Abcam; 2µg) antibody. Results were calculated from optical density of NF-κB specific bands.
Tissue Glucose uptake Tissue glucose uptake was measured ex-vivo with non-radioactive 2-deoxyglucose (2-DG) (26). EDL muscle is metabolically largely similar to gastrocnemius (27) and was used because of smaller diameter and better exchange with incubation buffer (28). Two muscle sections were incubated for 30' at 37°C under constant oxygenation with or without insulin (Humulin-R 600pmol/l) in isotonic buffer, pH=7.4, added with BSA (1mg/ml) and pyruvate (2mM). After 20-min incubation with pyruvate substituted with 2-DG (1mM), samples were snap frozen and kept at -80°C. After homogenization in ultrapure water followed by NaOH addition (0.07N), enzymes and endogenous NAD(P)H and NAD(P) were inactivated by 45-min incubation at 85°C. Equinormal quantities of HCl were then added, samples were cleared from debris by centrifugation (10000xg, 5min) and transferred to 96-well microplates for incubation Statistical analysis Groups were compared using Student t-test or one-way ANOVA followed by appropriate post-hoc tests. Bonferroni correction for multiple comparisons was applied. p<0.05
was considered statistically significant. UnAG lowers skeletal muscle ROS production UnAG lowered gastrocnemius H 2 O 2 and superoxide anion production rate, and this effect involved mitochondrial respiration-dependent ROS generation (Figure1A-C). NOS-dependent but not xanthine-or NADPH oxidase-dependent superoxide production was also reduced by UnAG ( Figure 1D-F) . UnAG-treated rats also had lower muscle oxidized-over-total glutathione, a marker of tissue redox state ( Figure 1G -H).
Results
EXOGENOUS
Tissue protein levels of SOD isoforms and activities of antioxidant catalase and glutathione peroxidase were conversely not modified by UnAG ( Figure 1I -L).
UnAG lowers tissue inflammation Protein expression of the NF-κB inhibitor IκB was higher in
UnAG-compared to saline-treated rats, with parallel reduction of pro-inflammatory NF-κB p65/p50 nuclear binding activity (Figure 2A-B) . UnAG also increased p50/p50 homodimer binding activity ( Figure 2B ), a transcription activator for anti-inflammatory IL-10 (30). UnAG treatment consistently resulted in anti-inflammatory changes in muscle cytokine patterns, with higher IL-10 expression and lower pro-inflammatory IL-1a and TNFα ( Figure 2C -G).
UnAG enhances insulin signalling and glucose uptake UnAG also led to insulin signaling activation with increased phosphorylation of AKT S473 , GSK-3β S9 , PRAS40 T246 and P70S6K T421/S424 ( Figure 3A-F) , consistent with activation of both mTORC complexes kinase activity. Changes in insulin signalling were paralleled by higher insulin-stimulated muscle glucose uptake ( Figure 3G ). These effects were further associated with enhanced IRS-1 S312 phosphorylation ( Figure 3B ), an mTORC-dependent negative feedback mechanism and marker for enhanced insulin signaling (31). To determine whether activating IRS-1 phosphorylations were also enhanced, we measured pIRS-1 Y612 and found no stimulation in UnAG-treated animals (Supplementary Figure 1A) , further indicating that UnAG-associated activation of insulin signalling occurs downstream of mTORC complexes but not at IR-IRS1 level.
In vivo effects of UnAG are tissue-specific In liver tissue, a non-statistically significant reduction in mitochondrial superoxide production was observed. ATP production was observed in obese mice compared to lean counterparts, but UnAG upregulation was associated with lower ATP production rates also in obese animals ( Figure 7B ).
UnAG modified muscle respiratory chain complex-related ATP production by shifting ATP synthesis towards complex I over complex II both in vivo and in vitro ( Figure 7D -E). Differently from UnAG, AG enhanced ATP production in C2C12 myotubes ( Figure 7C ). Liver ATP production was not modified by UnAG (Supplementary Figure 3G) .
Discussion
These studies demonstrated that 1) sustained UnAG administration in vivo leads to a) lower muscle ROS production and less oxidized tissue redox state; b) anti-inflammatory changes in tissue NF-κB activation and cytokine patterns; c) enhanced mTORC-dependent insulin signalling with higher insulin-stimulated muscle glucose uptake. 2) Muscle effects of UnAG are reproduced in a model of systemic circulating UnAG up-regulation with HFD-induced obesity, resulting in prevention of obesity-associated hyperglycemia and whole-body insulin resistance.
3) UnAG effects are dose-dependently confirmed in myotubes; differential effects of AG and UnAG are observed in vitro, thereby indicating that UnAG acts at least partly directly and independently of AG-regulated pathways. Finally, UnAG effects in vitro are abolished by autophagy inhibition, thereby indicating mechanistic involvement of autophagy in UnAG activities.
The current results show that UnAG negatively regulates skeletal muscle ROS production and inflammation, and these effects are indirectly supported by previous in vitro observations in nonmuscle cells (14, 16, 19) . In a recent study, UnAG reduced endothelial oxidative stress in models This finding is intriguingly consistent with emerging co-localization and functional interactions between NOS, nitric oxide (NO) and muscle mitochondria (37,38). In particular, NO production has been reported to enhance mitochondrial ROS generation (37) while UnAG was reported to reduce NO production induced by pro-inflammatory cytokines in various settings (39). Potential interactions between UnAG, NO and mitochondrial ROS generation should be directly investigated in future studies.
Sustained UnAG administration enhanced skeletal muscle insulin signalling downstream of mTORC complexes while not at IR-IRS-1 level, and these effects were paralleled by increased insulin-stimulated muscle glucose uptake. These changes are importantly in excellent agreement with, and provide a molecular basis for, clinical observations linking UnAG with preserved whole-body insulin sensitivity in humans (12, 13) . Interestingly, autophagy inhibition in vitro abolished UnAG activities on both mitochondrial ROS production and insulin signalling. These observations provide further strong support for a causal negative impact of mitochondrial ROS production on AKT-dependent insulin signalling, in agreement with previous observations (1-5).
Intriguingly, UnAG effects were associated with enhanced inhibitory IRS-1 S312 phosphorylation.
This seemingly paradoxical observation is however consistent with recent reports of IRS-1 S312 phosphorylation as a physiological negative feedback modulation following downstream signalling activation (31).
Results in Tg Myh6/Ghrl mice with chronic systemic UnAG over-exposure (19) confirmed effects of exogenous UnAG administration, and these results are supported by higher insulin sensitivity in a lean UnAG adipose transgenic model (17). Since plasma AG and IGF-1 are unchanged in Tg Myh6/Ghrl (19), our findings further confirm that UnAG effects are independent of changes in AG and its potential impact on GH-IGF1 through GHSR1 (7, 19 Overall, differential effects of ghrelin forms on muscle insulin signalling are fully consistent with clinical observations linking UnAG, but not AG to whole-body insulin sensitivity in humans (12, 13) .
It should be finally pointed out that UnAG-induced lower ROS production, lower inflammation and enhanced insulin signalling were associated with reduced or unchanged ATP production. In agreement with previous studies, high-fat fed animals conversely showed higher mitochondrial ATP production despite higher oxidative stress markers and insulin resistance (32), and this alteration could involve enhanced substrate availability through feed-forward mechanisms (32).
Our results therefore provide further evidence against a role for low mitochondrial function to primarily cause insulin resistance (41-45), conversely indicating UnAG as a novel modulator of muscle mitochondrial activity with negative impact on both ATP and ROS production in vivo.
Unchanged mitochondrial ATP production in vitro however does not support a direct role of UnAG to inhibit mitochondrial function, while it further indicates that reduced mitochondrial function is not a prerequisite for reduced ROS generation. Interestingly, UnAG modified complex-related ATP production by favoring complex I over complex II-related synthesis in vitro and in vivo, potentially reflecting preferential glucose over fat-derived substrate oxidation (46). Since glucose-related substrate oxidation may lower mitochondrial ROS generation (47,48), this mechanism could also contribute to inhibit ROS production. Further studies on interactions between UnAG and muscle mitochondrial function are warranted by the current results.
In conclusion, these studies demonstrated a novel role of UnAG to modulate skeletal muscle redox state, inflammation and insulin signalling. UnAG-treated rat muscle is characterized by lower mitochondrial ROS production, lower inflammation and enhanced insulin signalling and action. These effects are tissue-specific, they appear to be direct and independent of acylated hormone, and they could be at least partly mediated by UnAG-dependent stimulation of autophagy ( Figure 8 ). UnAG overexpression also prevents obesity-associated hyperglycemia and systemic insulin resistance as well as muscle oxidative stress, inflammation activation and impaired insulin signalling. The current findings collectively indicate UnAG as a potential novel treatment for obesity-associated metabolic alterations.
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